Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00148746
Status:
COMPLETED
Last Update Posted:
2010-06-09
First Post:
2005-09-06
Brief Title:
Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis
Sponsor:
Technische Universität Dresden
Organization:
Technische Universität Dresden
Study Overview
Official Title:
Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis
Status:
COMPLETED
Status Verified Date:
2010-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study was designed to test the hypothesis whether a standardized time-and score-oriented treatment following a strict evidence based algorithm is equally effective to a standard treatment regimen for moderate to severe atopic dermatitis
Study Type Mono-centre study patients are blinded physicians are randomized to either treat study- or controll group
Eligible are patients age 2 years or older with SCORAD 20 Duration 12 Months study visits every 4 weeks
Primary endpoint is Difference between Baseline SCORAD and mean SCORAD under treatment
Secundary endpoints are quality of life safety and economic burden in both treatment groups
Study Type Mono-centre study patients are blinded physicians are randomized to either treat study- or controll group
Eligible are patients age 2 years or older with SCORAD 20 Duration 12 Months study visits every 4 weeks
Primary endpoint is Difference between Baseline SCORAD and mean SCORAD under treatment
Secundary endpoints are quality of life safety and economic burden in both treatment groups
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None